Even though IFNβ by itself could also inhibit tumor growth, our previous observations indicate that only p19Arf+IFNβ treatment confers superior immune stimulation involving the NK cells, CD8+ and CD4+ T cells.21 Here we have evidenced the release all three classic markers of ICD (CRT, ATP and HMGB1), providing a likely mechanism for the results seen in our previous study. The gene discussed is CD8A; the disease is neoplasm.